Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 359

Related Citations for PubMed (Select 12717213)

1.
3.

One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.

Stratta RJ, Alloway RR, Lo A, Hodge EE; PIVOT Study Group.

Transplant Proc. 2004 May;36(4):1080-1.

PMID:
15194375
4.

Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.

Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ.

Transplantation. 2001 Nov 27;72(10):1637-43.

PMID:
11726823
6.

Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.

Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.

Transpl Int. 2001 Dec;14(6):396-404.

PMID:
11793037
7.

Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients.

Rogers J, Stratta RJ, Lo A, Alloway RR.

Transplant Proc. 2005 Oct;37(8):3552-4.

PMID:
16298658
8.

Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: a case-control study.

Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO.

Clin Transplant. 2000 Dec;14(6):572-9.

PMID:
11127311
9.

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

Nashan B, Light S, Hardie IR, Lin A, Johnson JR.

Transplantation. 1999 Jan 15;67(1):110-5.

PMID:
9921806
10.

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.

Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.

Liver Transpl. 2005 Jan;11(1):61-7.

11.

A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.

Ji SM, Li LS, Cheng Z, Cheng DR, Sun QQ, Chen JS, Sha GZ, Liu ZH.

Transplant Proc. 2007 Jun;39(5):1396-401.

PMID:
17580147
14.
15.

WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.

Dresske B, Zavazava N, Jenisch S, Exner B, Lenz P, El Mokhtari NE, Kremer B, Faendrich F.

Transplantation. 2003 Apr 27;75(8):1286-91.

PMID:
12717217
16.

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.

Bumgardner GL, Ramos E, Lin A, Vincenti F; Daclizumab Triple Therapy and Double Therapy Groups.

Transplantation. 2001 Aug 27;72(4):642-7.

PMID:
11544424
17.

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.

Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F; Phase III Daclizumab Study Group.

Transplantation. 2001 Sep 15;72(5):839-45.

PMID:
11571447
18.
19.

A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation.

Lo A, Stratta RJ, Alloway RR, Hodge EE; PIVOT Study Group.

Transplant Proc. 2005 Mar;37(2):1289-90.

PMID:
15848699
20.

A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience.

Soltero L, Carbajal H, Sarkissian N, Khan AJ, Brennan S, Gonzalez JM, Truong LD, Suki WN.

Transplantation. 2004 Nov 27;78(10):1560-3.

PMID:
15599323
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk